Guangdong CI Medicine

Guangdong CI Medicine is a clinical-stage biopharmaceutical company based in Guangzhou, China, dedicated to the discovery and development of innovative medicines for oncology and inflammatory diseases. The company's pipeline features a mix of biologics and small molecules, including its lead candidate CI-001, a recombinant humanized anti-PD-L1 monoclonal antibody, and CI-101, a selective PARP inhibitor. Guangdong CI Medicine aims to address unmet medical needs through rigorous R&D and strategic collaborations within the global biotech ecosystem. The company operates out of the Guangzhou Science City and focuses on bringing high-quality innovative therapies to the Chinese and international markets. It is recognized as a high-tech enterprise and continues to advance multiple programs through clinical trials.